The association of baseline variables with OS was modeled by Cox proportional hazards model and multivariable analyses were performed on significant variables.Īmong 388 patients, the median follow up was 5 years (range 0-51). Descriptive analysis was performed for each variable, and a comparison between patients who did or did not progress to advanced stage was performed using ANOVA for numerical covariates and chi-square test for categorical covariates. Kaplan-Meier curves for OS were generated for the whole cohort and by progression group. Overall survival (OS) was measured from time of diagnosis to date of death or last follow-up. Progression to advanced stage was defined as a highest overall TNMB stage of 2B-4B. Our primary endpoint was to identify variables associated with progression to advanced stage MF. Clinical data collected from the electronic medical record included demographics, laboratory values, disease characteristics, and therapy. We performed a retrospective review of 388 patients with early stage (1A-2A) MF at the Winship Cancer Institute of Emory University diagnosed between 19. We aimed to identify clinic features associated with progression to advanced stage MF in a large urban medical center. Prior studies suggest approximately 20% of early stage MF may progress to advanced stage, but risk factors for progression remain poorly studied, particularly among African American (AA) patients.
Advanced stage mycosis fungoides (MF) has a median survival of 3-5 years, while early stage MF is a chronic disease typically associated with an excellent prognosis and a median survival of 20 years or more.
0 kommentar(er)
